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Abstract
There is increasing emphasis on patient-centred research to support the development, approval and reimbursement of health
interventions that best meet patients’ needs. However, there is currently little guidance on how meaningful patient engagement may be achieved. An expert working group, representing a wide range of stakeholders and disciplines, was convened
by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
(ESCEO) and the World Health Organization (WHO). Through a structured, collaborative process the group generated practical guidance to facilitate optimal patient engagement in clinical development and regulatory decisions. Patient engagement
is a relational process. The principles outlined in this report were based on lessons learned through applied experience and
on an extensive dialogue among the expert participants. This practice guidance forms a starting point from which tailoring
of the approach to suit different chronic diseases may be undertaken.
Keywords Outcomes research · Patient engagement · Patient preference · Regulatory process · Treatment guidelines
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Introduction
The patient perspective is now increasingly recognized as
key in the development, conduct and evaluation of health
interventions. The 2015 World Health Organization (WHO)
report on healthy ageing identified that self-care plays a
critical role in health, with increasing patient participation
leading to better health outcomes in older adults including
improvements in physical activity, chronic pain and selfefficacy [1]. By involving patients at all stages of healthcare delivery and evaluation, the aim of enhancing self-care
in patients with chronic, non-communicable disease may
be achieved [2, 3]. Patient-centred care requires an understanding of a variety of patient-relevant components that
go beyond medical diagnostic and treatment-related issues.
They comprise psychosocial life-related challenges and a
focus on patient engagement that acknowledges that patients
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have an important role to play in their own healthcare. This
includes three pillars [4]:
1. Health literacy Enabling patient to read, understand and
act on quality health information;
2. Shared decision making and personal care planning
Enhancing self-determination and working with clinicians to select appropriate treatments or management
options [5];
3. Quality improvement Providing patient relevant feedback
on healthcare processes and outcomes.
Patient engagement in healthcare decisions respects
patient autonomy increases the likelihood that treatments
would be aligned with patient (group) needs and preferences
and ultimately leads to better outcomes for all concerned
[6]. The complementary impact on society includes reducing healthcare and research waste through the efficient use
of resources, as is the focus of health economics [7, 8]. This
applies at all levels in society and thus includes individual
clinical decisions. The promotion of patient-centeredness is
not limited to improving healthcare, but is relevant for the
entire life cycle of medicines.
To support the development, approval and reimbursement
of medical interventions that best meet patients’ needs, there
is increasing emphasis on patient-centred research through
the engagement of patients in identifying unmet needs [9],
the design and conduct of clinical studies [10], subsequent
regulatory assessments [11], post-marketing vigilance and
data collection. Patient engagement in clinical practice
guideline development is also recommended by many organizations [12–17]. Despite the many ongoing pilots, there is
currently little practical guidance on how effective patient
engagement may be facilitated. In this paper, we examine
how patients’ perspectives can inform the development of
clinical research and regulatory decisions. Our aim was
to generate practical guidance to facilitate optimal patient
engagement in these decisions and to raise awareness of its
value.

Methods
An expert working group meeting was organized by the
European Society for Clinical and Economic Aspects of
Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
(ESCEO) and the WHO, and held in Geneva, Switzerland,
on June 9, 2017. The working group comprised a global
representation of clinicians, outcome researchers, social
scientists, epidemiologists, health technology assessment
(HTA) and regulatory experts, pharmacists and patient
representatives. They were invited for their expertise and
knowledge regarding patient engagement and preference
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research. Agreement on the principles outlined in this article was based on an exchange of peer-reviewed publications
prior to the meeting and a 1 day interactive meeting with
short presentations and intense discussion among the meeting participants.
At the meeting, results from a literature review of methods for incorporating patients’ preferences into decisionmaking were presented followed by an introduction to
the nomenclature of patient engagement and a case study
on improving the quality of delivering integrated care by
involving older people (I. Araujo de Carvalho, I. Aujoulat,
M. Hiligsmann). Next, organizations including the European
Medicines Agency (EMA) and the Outcomes Measures in
Rheumatology (OMERACT) initiative introduced their
principles for engagement and presented lessons learned
through applied experiences (N. Bere, M. de Wit). After
the presentations, a prolonged discussion among the expert
group members took place, focused on the application of
these principles in different contexts, and shared conclusions
were reached.
Following the meeting, members of the writing group
(M. de Wit, C. Cooper, N. Bere, P. Tugwell, P. G. Conaghan,
C. Roberts, I. Aujoulat) drafted a first report on the meeting, which was reviewed and commented on by all authors.
In this resulting article, we define the concepts of patient
involvement at different levels and discuss patient engagement within the three areas: patient preference elicitation,
outcomes research and regulatory processes. Case studies
from the EMA and the Group for Research and Assessment
of Psoriasis and Psoriatic Arthritis (GRAPPA) (following
OMERACT principles) exemplify our approach.

Definitions
There are complementary approaches to capturing patients’
perspectives in health research and health services innovation, to ensure that research and development of medical
interventions adequately meet patients’ needs. Patients in
different numbers may contribute to subsequent phases of a
process, carrying out a variety of tasks and on different levels. Different terminology is used, and it is first important to
clarify these concepts [18, 19]. We distinguish the following
patient roles in patient involvement.
Consultation involves participation of patients and/or
their representatives as study participants; their role may be
to trial an investigational agent and/or to provide information
on their own individual experience. This level of involvement requires predominantly a flow of information in one
direction from patient to researcher. Protocols for participation in a clinical trial or other means of data collection such
as surveys, interviews or focus groups are well developed
and highly regulated through the Helsinki declaration.

Aging Clinical and Experimental Research (2019) 31:905–915

Advice is provided by an informed patient, e.g., by discussing new developments and sharing personal knowledge
and experience, or by reviewing research grant applications
or a scientific publication. The involvement is often limited
to one occasion.
Collaboration may be undertaken through multiple roles,
e.g., patient research partner (PRP), or patient expert [18].
A patient expert may be defined as an ‘expert’ in their own
disease and its management, and someone who is equipped
to look further than their own personal experience of the
disease. Patient collaboration takes place on a collective
level and influences the aims, design and conduct of a study
through dialogue, two-way communication in partnership
with other stakeholders.
Control is achieved when a patient organization takes the
lead, determines the research gap or research questions, controls the study and owns the data.
We will use the terms engaging patients and patient
involvement as synonyms for the process of enabling people
with a long-term condition to provide a meaningful contribution to research or the improvement in healthcare services.
Patient empowerment is a process whereby the person develops more control over decisions and actions that affect their
own life and health [20, 21]. This involves helping a person to learn to think critically and make informed decisions
about self-care to reduce symptoms from the chronic disease
[22]. There is increasing recognition that patient empowerment is a core element of quality oriented, sustainable health
systems of the future [23]. However, because the focus of
this article is on engaging patients in the context of health
research and medicine development and authorisation, we
will not elaborate on patient empowerment.

907

Qualitative and quantitative methods could be used to
identify what is important to patients with respect to healthcare decision-making. Stated preference methods have been
increasingly used in HTA to elicit preference [24]. The most
often used stated-preference methods include discrete choice
experiment (DCE) [27, 28], best–worst scaling (BWS)
[29], and analytical hierarchy process (AHP) [30, 31]. As
an example, Rothery et al. used a DCE to assess patient
preference for treatment-related benefits and risk of disease
relapse in the management of low disease states of psoriatic
arthritis (PsA) [32]. The study found that among patients
in low disease states of PsA, respondents were willing to
accept greater risk of relapse (up to 30% increased risk) for
an improvement in the side effects of sickness and nausea
and health status.
Patients’ preferences are nowadays increasingly sought in
healthcare decision-making. By example, the US Food and
Drug Administration (FDA) has developed an initiative for
the consideration of patient preferences for multiple endpoints in development assessment of new health technologies in medical devices (FDA Medical Device Patient Preference initiative) [33]. The FDA has also provided definitive
guidance on the use of patient reported outcome measures
for use in trials to support labelling claims [34], and the
EMA has developed guidance on the use of patient reported
outcomes in anticancer studies [35].
In Europe, there are several initiatives which aim to
increase the use of patient preferences in policy decisionmaking, which include:
• The German Institute for Quality and Efficiency in

Patient engagement in patient preference
elicitation

•

The assessment of patient preferences could help to improve
disease management, facilitate shared decision-making and
improve adherence, whilst increasing the use of patient preferences in health policy making may improve the quality
of decisions and increase efficiency [24]. For example, the
collection of individual preferences may inform regulatory
review processes [25]. Preference studies offer a systematic
approach to gathering information on the distribution of
preferences in a population and the implications on patients’
acceptance of specific treatments. Although the usefulness
of stated preference studies is still not well established, such
studies, along with other methods such as focus groups and
expert opinions, have the potential to become an important
tool for gathering patient views in a systematic way to estimate treatment acceptability and concordance, and thus
inform regulatory and treatment decisions [26].

•

•

•

Healthcare (IQWiG) may include patient preference in
cost–benefit assessment as part of the economic evaluation.
The National Institute for Health and Care Excellence
(NICE) assessment of utility impact involves the elicitation of general population preferences.
The EMA piloted swing weighting to elicit patient preferences for benefit/risk analysis for market authorization
[25]. This was followed up with a larger study eliciting
preferences of over 550 multiple myeloma patients on
benefits and risks of cancer treatments to illustrate how
such data may be used to estimate patients’ acceptance
of new treatments [26].
The PROTECT (Pharmacoepidemiological Research on
Outcomes of Therapeutics by a European Consortium)
project, conducted by the Innovative Medicines Initiative
(IMI) and coordinated by the EMA, focuses on the question of public/patient involvement in regulatory processes
[36].
IMI PREFER (Patient Preferences in Benefit-Risk
Assessments during the Drug Life Cycle) project initiated late 2016 focuses on eliciting patient perspectives
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for use in benefit-risk assessment (BRA) and health technology assessment (HTA) [37]. PREFER will result in
recommendations regarding the best ways to perform and
include patient-preference in the decision-making process of industry, regulatory authorities and HTA bodies.
These initiatives have focused on the role of patient preferences through the life cycle of medicines and for regulatory decision making. Incorporating the preferences of
patients in clinical decision-making (shared decision making) is another dimension that could be the focus of future
initiatives [38].

Patient engagement in clinical outcomes
research
Initiatives to increase patient engagement in aspects of
clinical research have been undertaken by a wide range
of research communities. Engagement may involve the
patient, relatives, informal carers or patient representatives,
all of whom can give a relevant stakeholder perspective on
research and healthcare innovation. The patient engagement
process is evolving, and roles for patients may vary with
increasing degrees of involvement, from steering group
members, committee or working party members with voting rights, to PRPs or Delphi participants [39].
Here we explore the experience of the OMERACT Initiative. OMERACT sets out to achieve consensus about
core outcome sets (endpoints) for clinical trials and longitudinal observational studies in rheumatology, with patient
involvement an integral part of the process [10]. OMERACT
defines the PRP as a person with a relevant disease who
operates as an equal member in the research team to provide the patient perspective in every phase of the study [40].
PRPs share decision-making power with professionals, can
take on any role similar to all other members and have full
voting rights at the biannual meeting [18]. Practical recommendations for patient engagement in research teams were
published in 2016 [40].
Other initiatives that have developed rules and pilots to
include PRPs in their research activities:
• European League Against Rheumatism (EULAR) pub-

lished practical recommendations for the inclusion of
patient representatives in scientific projects [41]. They
are widely followed by all working groups developing
disease management recommendations for rheumatic
conditions.
• COMET (Core Outcome Measures in Effectiveness Trials) brings together people interested in the development
and application of agreed standardised outcome sets used
in clinical research [42]. COMET has established a Peo-
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ple and Patient Participation, Involvement and Engagement (PoPPIE) Working Group that develops practical
resources for PRPs.
• The Standardised Outcomes in Nephrology (SONG)
initiative aims to establish a set of core outcomes and
outcome measures across the spectrum of kidney disease
for trials and other forms of research. The outcomes will
be developed based on the shared priorities of patients,
caregivers, clinicians, researchers, policy makers and relevant stakeholders. This will help to ensure that research
is reporting outcomes that are meaningful and relevant to
patients with kidney disease, their family and their clinicians. Currently in development are core outcomes for
haemodialysis (SONG-HD), transplantation (SONG-Tx),
peritoneal dialysis (SONG-PD) children and adolescents
(SONG-Kids), and polycystic kidney disease (SONGPKD) [43].
• Based on the concept of value-based healthcare, the
International Consortium for Health Outcomes Measurement (ICHOM) brings together global teams of physician
leaders, outcomes researchers and patient advocates to
define Standard Sets of outcomes for clinical practice that
matter most to patients. ICHOM captures the patient perspective both by conducting qualitative research to collect data on patient preferences as by active involvement
of patient experts in the consensus building process. The
final standard sets then drive adoption to enable healthcare providers globally to compare, learn and improve
[44].
• The Patient-Centered Outcomes Research Institute
(PCORI) has developed the PCORI Engagement Rubric,
which provides a framework for operationalizing engagement to incorporate patients and other stakeholders in all
phases of research. The aim is to encourage active and
sustained engagement of patients as partners in planning,
conducting and disseminating research, to improve clinical decision-making and outcomes [45].

Case study 1: GRAPPA core outcomes set in PsA
GRAPPA is a non-profit organisation focused on identifying
and initiating research projects, advancing standardized criteria for PsA registries and developing treatment guidelines.
GRAPPA was formed in 2003 of > 600 rheumatologists, dermatologists, radiologists, geneticists, methodologists, epidemiologists and biopharmaceutical industry representatives
with an interest in PsA and psoriasis research. Since 2013,
patient research partners participate in the annual meetings
and a variety of working groups. A best practice case study
of patient participation in the update of the PsA core domain
set is outlined here [46, 47].
The OMERACT-GRAPPA PsA working group met to
review the existing PsA core set [48] based on the patient

Aging Clinical and Experimental Research (2019) 31:905–915

perspective as well as new research findings and further
develop PsA responder indices. The group discussed the
need to revise the PsA core set, and opportunities to add,
move, or merge existing domains to better integrate the
patient perspective and to remove redundancy; and how to
incorporate the core set in a composite index [49].
OMERACT recommendations for patient involvement
were followed and included (Fig. 1):
1. Active partnership of five PRPs in the working group
and one PRP in the Steering Group.
2. International focus group study representing five continents and including seven countries.
3. Delphi study.
4. Consensus meeting.
New domains were identified through systematic literature review, international focus groups exploring the
opinions and experiences of people with PsA and two international surveys with patients and physicians to prioritise
domains. Consensus was achieved through an international
face-to-face expert meeting with equal representation of
patients and physicians to agree on the most important
domains, and voting at the OMERACT 2016 conference.
PRPs were involved at all phases of the process. As a result,
the updated PsA core domain set incorporates patients’ and
physicians’ priorities and includes the domains of: musculoskeletal disease activity, skin disease activity, pain,
patient global, physical function, health-related quality of
life, fatigue and systemic inflammation [47].
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collaboration. Preserving the patient perspective throughout
the research process is of great importance and following
from an unanticipated workload for PRPs and researchers
it may be difficult to keep PRPs and researchers motivated
to collaborate.
Participation requires multiple forms of engagement and
should always be tailor-made, there is no common methodology or application that fits every research context. In addition, participation requires a willingness for mutual learning,
and the role of the principal investigator is key in providing
adequate support to patients. Fruitful participation always
requires additional resources to be allocated to the process,
with extra effort in time, money and energy. A structural
approach guarantees sustainability of participation.

Patient engagement in regulatory processes
Since establishment of the EMA in 1995, interaction with
patients has developed progressively with the creation of a
Framework for interaction with patient and consumer groups
in 2005, a Patients and Consumers Working Party (PCWP)
in 2006, including representatives from 20 organisations and
a dedicated ‘public engagement’ department in 2014.
The EMA has increasingly incorporated the patients’
voice within its regulatory activities by way of pilot projects
testing the various engagement methodologies, in collaboration with its network of patient organisations [50, 51]. There
are now processes to include patients at all stages along the
regulatory lifecycle (See Case Study 2).

Lessons learned

Case study 2: EMA methodology on patient
engagement, a progressive journey

Challenges identified were to ensure broad representativeness of patients’ perspectives in demography, geography,
disease severity and in numbers, which entails a significant level of communication and efforts to enable equal

Patient engagement occurs at all steps along the medicine regulatory lifecycle (Fig. 2). As the EMA progressed
with involving patients in its activities, it became apparent
that there were different levels of patient’s representation,

Fig. 1  Patient involvement in
all steps of the update to the
core outcome set for psoriatic
arthritis
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Fig. 2  Patient involvement can occur at all steps along the medicine development and regulatory lifecycle

depending on the nature of the activity. The different categories are: representing the patient community; representing
their own organisation, and patient as individual experts.
In the pre-submission phase of development, examples
of where patients can contribute to EMA discussions on the
design of clinical trials include:

• Identify the most suitable patients/groups to involve in

• Selection of end-points.
• Defining target population, inclusion/exclusion criteria.
• Study duration, treatment administration, formulation

•

•
•
•
•

and dosage.
Clinical relevance versus statistical significance.
Identification of risk potential.
Significant benefit (added-value) over existing therapies.
Ethical aspects, informed consent.

Lessons learned
It also became apparent that for optimal and mutually beneficial engagement to occur, the following elements are vital:
• Define the role of the patient for each specific activity

and ensure that all involved parties are informed. This
facilitates participation and also manages expectations
from all angles.
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•

•
•

each situation, taking into account representation and
confidentiality aspects.
Establish a range of engagement methodologies and
assess for each case which method is most suitable for
the situation (e.g., face-to-face, in writing, surveys,
committee meetings, preference elicitation).
Provide individualised support and training, tailored to
the individual and the activity, e.g., training sessions,
videos, info-sheets, webpages, one-to-one support. To
aid training, the European Patients’ Academy on Therapeutic Innovation (EUPATI) has developed patient
education resources in key areas of non-clinical and
clinical development, clinical trials, regulatory affairs
and health technology assessment [52, 53].
Provide feedback to all involved, especially so that the
patient sees that their input is valuable.
Continuous monitoring and reporting on interactions,
and refining procedures according to feedback received.

Challenges identified were in finding suitable patients
(e.g., language barrier, availability) while ensuring representativeness and in knowing how to also gather validated
information from larger groups. Potential conflicts of interest need to be handled sensitively. Compensation is also
an area requiring attention. Demonstrating the value and/
or impact of patient involvement in a quantitative manner

Aging Clinical and Experimental Research (2019) 31:905–915
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Table 1  WHO-ESCEO Principles for engaging patients in health research, treatment guidelines and regulatory processes. Table reprinted from
de Wit et al. [54] with permission from Elsevier
9 principles for best practice
1. Patient perspective
2. Engagement
3. Transparency
4. Representation
5. Multiple inputs
6. Support
7. Expertise
8. Resources
9. Monitor

The perspective of patients is pivotal in health research, treatment guidelines, and the authorization of medicines
Capturing patients’ perspectives requires multiple forms of engagement that are complementary; the strategy should be
tailored to suit different chronic diseases and contexts
Transparency for all stakeholders about the role of patients in the process facilitates participation and manages expectations from all perspectives
Broad representativeness of patients’ perspectives in terms of demography, geography, disease severity and sample size
must be ensured
Involvement of at least two patient experts throughout the research, assessment and deliberation processes ensures that
the patient perspective is preserved and increases the validity of the outcomes
Providing adequate information, support and feedback to patient representatives is key to effective engagement
Teaching researchers the knowledge and skills required to support public engagement should always be considered
Productive participation always requires resources to be allocated to the process, with extra effort in time, money and
energy
Continuous monitoring and measuring of interactions will be vital for refining procedures according to feedback

while avoiding subjectivity is a challenge; however, qualitative methods can be of value provided that there is sufficient reflexivity and transparency. The trend in public
health is now to use mixed methods designs.

Conclusions: principles for engaging
with patients
Engaging with patients helps to bridge the gap between
health research, policy and patient-centred practice,
increases transparency and patients’ adherence to treatments,
reduces waste and leads to more meaningful regulatory outcomes. Patient engagement should be initiated in a stepwise
approach through which all parties can learn together and
identify the format that works best for all involved. At all
stages of engagement, provide support, define roles, manage
expectations and give feedback, to ensure that engagement
is mutually beneficial. In this way, ultimately everyone can
benefit from knowledge sharing.
Patient engagement is a relational process, and the nine
principles outlined here (see Table 1) [54], form a starting point from which tailoring of the approach to suit
different chronic diseases and other healthcare context
needs may be undertaken. Overarching principles include
the recognition that the perspective of patients is pivotal
in outcomes research and the decision-making process of
medicine authorisation that earlier involvement of patients
is always better and that involvement at all stages is necessary. Patients should be offered the possibility to consult
each other on experience-based views; furthermore, patients
sometimes need to cancel their presence due to health issues.
To ensure proper representation, inviting at least two PRPs is
recommended [55]. Finally, acknowledgement of input and

feedback to patients is essential, and integrated knowledge
translation is desirable [56].
In this article, we acknowledge that there are different
levels of patient engagement, all equally valuable and complementary, and that the degree of patient participation and
level of power or authority should not be mandatory but
may be tailor-made to suit the individual research purpose.
Patient engagement is an evolving concept, and the research
agenda for future refinement of the process will include the
development of new methodologies to assess the impact
of patient engagement and novel ways to enhance the significance of existing methods for engagement, in order to
emphasize the role of the patient voice in health research,
treatment guidelines and regulatory processes. The impact
of patient engagement, in terms of added value, but also
cost and potential downsides is currently poorly understood.
Reasons for this include a lack of consensus on a validated
methodology or tool to measure impact, and a lack of consensus on the important outcomes of patient engagement;
people and stakeholder groups have different expectations
and objectives regarding patient engagement, and thus
require different methodologies and outcomes for evaluation.
Another challenge is that we, as an expert group, all agree
that principal investigators and stakeholders should invest
in support, information, education and feedback to patient
experts (see Panel); however, there is a growing awareness
that it does not make sense to train patients in the medicine development cycle, without simultaneously preparing
researchers for their role and task of engaging patients in
that process. Thus, there is a need to explore both the benefits and downsides of educating patient experts as well as
exploring the needs of researchers for guidance, coaching
and training [57].
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